Results in 164 patients who underwent allogeneic marrow transplantation following busulfan and cyclophosphamide over a 15 year period were analyzed. Age (median 37, range 14-66 years) did not significantly affect the incidence of graft-versus-host disease (GVHD), but patients who received methotrexate with cyclosporine had a significantly lower incidence (P = 0.002) of chronic GVHD compared to those who received methylprednisolone with cyclosporine. Hepatic veno-occlusive disease (VOD) occurred less frequently in chronic phase patients (P = 0.002) and in those transplanted shortly after diagnosis (P = 0.001). Five year leukemia-free survival (LFS) for the entire group was 49% (95% CI 41-57%). For 102 patients who underwent transplantation in chronic phase, results were significantly improved by transplantation at a short interval following diagnosis, particularly within 3 months (P = 0.01), by the use of methotrexate and not corticosteroids for GVHD prevention (P = 0.03), and by use of HLA-identical sibling donors (P = 0.01). Age was not a significant adverse prognostic factor and transplantation was successfully performed in individuals up to age 66. Allogeneic transplantation in CML, including older patients and those with unrelated donors, can be most safely and effectively performed shortly after diagnosis. Bone Marrow Transplantation (2000) 26, 1037-1043. Keywords: allogeneic transplantation; CML; BuCy Allogeneic marrow transplantation is the preferred treatment for 'young' patients with CML who have human leukocyte antigen (HLA)-identical sibling donors. However, because most individuals with CML are older than the 40 or 50 year threshold below which early transplantation is generally recommended 1-3 or lack histocompatible sibling donors, only a small proportion undergoes allogeneic mar-
row transplantation shortly after diagnosis. Many patients undergo transplantation beyond the first year after diagnosis [4] [5] [6] and/or after they have progressed to an accelerated or blastic phase, [5] [6] [7] circumstances which compromise success rates. [4] [5] [6] [7] [8] [9] [10] Delay in transplantation often results from hesitancy by patients and treating physicians because of the early mortality associated with allogeneic marrow transplantation and controversy regarding its optimal timing. 11 Improved success rates would directly benefit patients undergoing this procedure and would likely extend its timely application to individuals who otherwise might delay or avoid transplantation.
We previously modified a preparative regimen of Bu and Cy developed by Santos et al 12 and used primarily in AML, to the BuCy 2 regimen and studied its effectiveness in patients with CML. 13, 14 Favorable results of single 13, 14 and multi-institutional trials 15 using HLA-identical sibling donors led to randomized studies which yielded survival curves similar to those achieved with cyclophosphamide and total body irradiation (Cy/TBI) 16, 17 and suggested less acute toxicity with BuCy. 16 Although less commonly used as preparation for unrelated transplantation, BuCy 2 has also proven effective in that setting. 18, 19 Legitimate concerns about limited follow-up of published studies and concerns about graft failure, particularly in unrelated transplantation, 17, 19, 20 hepatic VOD, 21 and long-term complications, particularly obstructive brochiolitis, 22 temper enthusiasm for the use of this regimen. We report here long-term results in 164 patients with CML who have undergone allogeneic transplantation from related or unrelated donors following busulfan and cyclophosphamide over a 15 year period. The influence of factors, particularly those controlled by patients and physicians, are analyzed.
Patients and methods
Between March 1984 and February 1999, 164 patients with Philadelphia chromosome-positive CML underwent a first allogeneic marrow transplant from an HLA-identical or one antigen mismatched related or unrelated donor. All patients who underwent marrow transplantation according to protocol were included in the analysis. Protocols were approved by the Institutional Review Board. All patients provided written informed consent. Analysis was based on data available as of 1 July 1999.
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Tissue typing
HLA matching was based on serologic typing or molecular methods for HLA A, B, and DR antigens. From 1993 on, typing for HLA DR beta-1 alleles was performed by DNA hybridization with sequence-specific oligonucleotide probes. A single mismatch at HLA A, B, or DR was permitted for related donors, and detection of a single minor mismatch of HLA A, B, or DR beta-1 was permitted for unrelated donors 35 years or younger.
Staging
Diagnosis required demonstration of the Philadelphia chromosome. Accelerated and blastic stages were defined according to published definitions. 23 
Preparative regimen and supportive care
Patients were prepared for transplantation with Bu 16 mg/kg and Cy 120 mg/kg, as previously reported. 13 Beginning in 1993, patients with accelerated (except for cytogenetic evolution only) or blastic phase disease received a modified regimen of Bu 14 mg/kg, etoposide 50 mg/kg, and Cy 120 mg/kg. Chemotherapy doses were initially based on the lower of the ideal body weight (IBW) or real body weight (RBW), except for patients whose RBW exceeded their IBW by more than 20%, in whom doses were based on an adjusted IBW (AIBW). Beginning in December 1994, both Bu and Cy doses in all patients were based on an AIBW, consisting of IBW + (0.25[RBW − IBW]). Cyclosporine (CsA) and methylprednisolone were administered as previously described 13 for GVHD prevention to November 1991. Subsequently, cyclosporine and methotrexate were given for graft-versus-host disease (GVHD) prophylaxis. 16 Patients were placed in isolation rooms supplied with positive-pressured filtered air. Antibiotics were administered for prevention of bacterial infection. Growth factors were not routinely administered.
Hematopoietic recovery
Engraftment was judged to have occurred on the first of 3 consecutive days that the neutrophil count exceeded 0.5 × 10 9 /l. Platelet recovery was defined as a platelet count exceeding 20 × 10 9 /l without platelet transfusion. Engraftment of donor cells was demonstrated by in situ hybridization with Y-body-specific probes in sex mismatched transplants or by cytogenetic heteromorphisms. Graft failure was defined as failure to achieve a neutrophil count greater than 0.5 × 10 9 /l for at least 3 consecutive days, a decrease in the neutrophil count below 0.2 × 10 9 /l for at least 3 consecutive days following initial engraftment, or documented loss of donor cells.
Complications
Acute 24 and chronic GVHD, 25 hepatic VOD 21 and obstructive bronchiolitis 26 were defined and graded according to previously published criteria.
Relapse
Relapse was defined as detection of the Philadelphia chromosome on two separate occasions after day 50 or hematological evidence of recurrent CML. Marrow and/or peripheral blood cytogenetic studies and, from March 1991, reverse transcriptase-polymerase chain reaction (RT-PCR) studies for BCR-ABL transcripts were routinely performed at 30 days, 100 days, 6 months, 1 year, and then on a yearly basis following transplantation.
Statistical analysis
Univariate analyses of survival and event-free survival used the Kaplan-Meier product limit method 27 with logrank tests 28 of survival curves. Cox proportional hazards regression 29 was used in multivariate analyses to identify possible prognostic factors.
Results
Patient characteristics
Clinical characteristics of the 164 patients who underwent transplantation are presented in Table 1 . Median patient age was 37 (range 14-66) years. Sixty-nine patients (42%) were 40 or older and 16 (10%) 50 or older. One hundred and two chronic phase patients are described in Table 2 . Table 1 Characteristics of 164 patients undergoing allogeneic bone marrow transplantation for chronic myelogenous leukemia
Number of Percentage patients
Age (median 37; range 14- 
Engraftment
Four patients died prior to day 28 and were not evaluable for engraftment. Four patients failed to achieve neutrophil counts of 0.5 × 10 9 /l for 3 consecutive days. Two patients who achieved such counts had a subsequent decrease in neutrophil count to Ͻ0.2 × 10 9 /l. Thus, graft failure occurred in six of 160 evaluable patients (4%). All of these patients experienced primary graft failure. Two had blastic phase disease, one with extensive fibrosis, and one received marrow from a family DR mismatched donor. Three received marrow from unrelated donors. Granulocyte counts greater than 0.5 × 10 9 /l were achieved at a median of 19 (range 11-47) days following transplantation. The median duration of a granulocyte count Ͻ0.5 × 10 9 /l was 14 days. Platelet engraftment occurred at a median of 23 (range 15-117) days.
Transplant-related complications
GVHD: Twenty-two percent of evaluable patients developed grade II acute GVHD; 14% developed grade III or IV acute GVHD. Fifty-one percent developed chronic GVHD. By multivariate analysis, advanced stage of disease did not adversely influence the incidence of acute (P = 0.24) or chronic GVHD (P = 0.98). Neither did older age affect the incidence of acute (P = 0.92) or chronic (P = 0.72) GVHD. Patients who received marrow from HLAidentical siblings experienced lower incidences of acute (P = 0.03) and chronic (P = 0.02) GVHD.
Of 102 patients with chronic phase disease, 40 (39%)
received CsA/methylprednisolone and 62 (62%) CsA (or FK-506 in 11) and methotrexate. Patients who received methotrexate had a lower incidence of chronic (P = 0.002), but not acute GVHD (P = 0.13).
Hepatic VOD: Patients transplanted in chronic phase had a significantly lower incidence of hepatic VOD (31%) than those in accelerated (63%) or blastic phase (59%) (P = 0.002). A shorter interval from diagnosis to transplantation was associated with a significantly lower incidence of VOD (P = 0.001). Patients transplanted less than 3 months after diagnosis had a 12% incidence, 3-12 months a 21% incidence, and Ͼ12 months a 60% incidence of developing VOD. Patients with HLA-identical sibling donors had a significantly lower incidence of VOD (P = 0.03). Age (P = 0.37), prior busulfan (P = 0.22) or interferon (P = 0.13), the use of methylprednisolone in GVHD prevention (P = 0.16), and the use of AIBW in all patients (P = 0.17) were not significantly associated with VOD.
Relapse
The estimated relapse incidence at 5 years was 7% (95% CI 0-14%) for patients in chronic phase, 18% (95% CI 1-35%) for those in accelerated phase, and 31% (95% CI 2-60%) for those in blastic phase at the time of transplant. No patients relapsed more than 3 years following transplantation. Five patients remain alive following relapse, including three presently in cytogenetic remission following infusion of donor lymphocytes.
Detection of BCR-ABL
A total of 522 RT-PCR studies were performed on marrow or blood from 81 patients. Fourteen of 60 chronic phase patients had at least one positive study following transplant but only three had positive studies beyond 6 months. All three developed cytogenetic or hematologic relapse. Ten of 21 advanced stage patients had positive studies following transplantation. All four who had positive studies beyond 6 months relapsed.
Causes of death
Seventy-six patients have died. Causes of death are described in Table 3 . 
Leukemia-free survival
Eight-three patients are leukemia-free survivors a median of 5.8 years (range 0.5-15 years) from transplantation. The estimated 5-year leukemia-free survival (LFS) for the entire group was 49% (95% CI 41-57%). The 5-year LFS for patients who underwent transplantation while in chronic, accelerated, and blastic phase were 59% (95% CI 49-69%), 40% (95% CI 24-56%), and 22% (95% CI 3-41%), respectively ( Figure 1 ). Patients transplanted in chronic phase experienced significantly better LFS than did patients in accelerated (P = 0.005) or blastic (P = 0.0001) phase.
For patients who underwent transplantation while in chronic phase, a longer interval from diagnosis to transplant (P = 0.0003), the use of methylprednisolone in GVHD prevention (P = 0.03), and the use of donors other than HLAidentical siblings (P = 0.01) were, in multivariate analysis, adverse prognostic variables. LFS for patients transplanted less than 1 year following diagnosis was significantly better than those beyond 1 year (P Ͻ 0.001) as was the incidence of non-relapse mortality (P = 0.01). Chronic phase patients transplanted within 3 months of diagnosis had a better LFS than those transplanted beyond 3 months (P = 0.01) ( Figure  2 ). Patient age (P = 0.85) and prior busulfan (P = 0.81) or interferon (P = 0.97) were not significant variables.
Patients in chronic phase transplanted within 1 year of diagnosis with marrow from HLA-identical siblings had a 5-year LFS of 78% (95% CI 66-90%). Patients receiving transplants less than 3 months from diagnosis had a 5-year LFS of 91% (95% CI 74-100%).
For chronic phase patients undergoing MUD transplants, those receiving transplants within 1 year of diagnosis had a significantly better 5-year LFS (P = 0.03) than those transplanted beyond 1 year (64% (95% CI 43-85%) compared to 36% (95% CI 11-51%)). Table 4 describes prognostic variables and relative risks for patients transplanted in chronic phase. 
Figure 2
The probability of event-free survival for patients with chronic phase chronic myelogenous leukemia undergoing allogeneic transplantation less than 3 months, 3 months to 1 year, or more than 1 year from diagnosis. WBC = white blood cell count; BMT = bone marrow transplantation; GVHD = graft-versus-host disease; AIBW = adjusted ideal body weight.
Long-term complications
Obstructive bronchiolitis was diagnosed in seven of 91 (8%) patients who survived at least 2 years following transplantation. All had chronic GVHD. Six had received methylprednisolone for GVHD prevention. Hypothyroidism developed in three patients (3%). Four men fathered a total of seven children; no women became pregnant following transplantation. One patient developed a squamous cell carcinoma of the oropharynx 2 years after transplantation. Two patients developed basal cell carcinomas. No other patients developed a second malignancy.
Discussion
This study presents the results of a large number of patients with CML treated with busulfan and cyclophosphamide at a single institution. It should be noted that this study is non-randomized and comparisons to other regimens are retrospective. The results demonstrate sustained effectiveness. The low incidences of BCR-ABL transcript detection and of cytogenetic and hematologic relapse compare favorably to those reported following Cy/TBI. [2] [3] [4] [5] [6] [30] [31] [32] Prior studies have suggested that this regimen may be more effective than Cy-TBI in eradicating CML. 14, 15, 17 Transplantation within 1 year of diagnosis has been previously correlated with a significantly better outcome than transplantation performed later in the course of disease. [8] [9] [10] However, this has not been consistently seen, [33] [34] [35] and early transplantation is not uniformly recommended. The impact of delay is clearly magnified in the present study and might be influenced by the preparative regimen. Optimal results were achieved when transplantation was performed within 3 months of diagnosis. Patients transplanted within 6 months of diagnosis in Seattle have fared better than their conterparts whose transplants were delayed beyond 6 months. 34 These data raise important questions about strategies which delay transplantation.
Many patients with CML are initially treated with interferon-␣; transplantation is considered in those with inadequate responses. However, an appropriate trial to achieve maximal cytogenetic response in patients receiving interferon-␣ is approximately 1 year. 11, 23, 36 Futhermore, recent data support a benefit from a 3 month interval between interferon and transplantation. 37 Thus, an appropriate trial and hiatus from interferon-␣ before allogeneic transplantation significantly delays and therefore compromises results with transplantation.
The poorer results in patients who underwent transplantation at longer intervals from diagnosis in this study resulted predominantly from treatment-related mortality. Prolonged treatment of CML may predispose patients to complications of transplantation and treatment-related mortality, perhaps through subclinical damage to vital organs, including the liver (which might in turn affect metabolism of busulfan and cyclophosphamide). The significantly higher incidence of hepatic VOD in patients with longer intervals from diagnosis to transplantation supports this hypothesis and may help explain the impact of delay on LFS. The low incidence of VOD in patients transplanted shortly after diagnosis may be related to low busulfan levels compared to other diseases, eg non-Hodgkin's lymphoma and multiple myeloma. 38 Clift et al 16 previously recognized that the higher incidence of VOD with busulfan compared to TBI occurs only in advanced stage or heavily pretreated patients.
Clinical results, including those of the present study, support the significance of recent pharmacokinetic studies. The use of AIBW has been shown to minimize differences in busulfan clearance in underweight compared to obese patients. 38 While no significant improvement in LFS was detected when AIBW was used in non-obese patients, all obese patients were dosed according to AIBW in this study. Furthermore, while decreased clearance of busulfan occurs in specific diseases, eg non-Hodgkin's lymphoma, suggesting that doses should be lowered, the 16 mg/kg dose appears appropriate for patients with CML. 38 Finally, the role of busulfan exposure in increasing exposure to hydrocyclophosphamide 39 probably accounts for the unexpected
Bone Marrow Transplantation degree of immunosuppression provided by this regimen, permitting its use with well matched, unrelated donors. Older, otherwise healthy patients can be safely transplanted following BuCy 2 . Neither hepatic VOD, GVHD nor LFS were adversely effected by older age. Approximately 80% of patients, including many between 40 and 66 years of age, transplanted with sibling donors within the first year after diagnosis and a higher proportion of those transplanted within 3 months are likely to be cured using current techniques. Patients and referring physicians should consider allogeneic transplantation shortly after diagnosis in many patients who are not currently considered. Allogeneic transplantation should be the treatment of choice in most patients with HLA-identical siblings, even in this 'older' age group. Results using matched unrelated donors demonstrate that BuCy 2 is effective and safe in the unrelated setting when transplantation is performed shortly after diagnosis.
Available data suggest that BuCy 2 is at least equivalent and may be superior to Cy/TBI as preparation for allogeneic transplantation in most patients with CML. Although two randomized studies have failed to demonstrate a significant difference in leukemia-free or overall survival in patients receiving BuCy 2 compared to CyTBI, it appears to have less acute toxicity, 16 including a shorter duration of neutropenia, and increased effectiveness. 17 Its use is further favored by its greater ease of administration, lesser expense, and its association with fewer and less severe delayed effects, eg second malignancies, hypothyroidism, and sterility. 40 While consideration should be given to a recent report of a higher incidence of chronic GVHD and bronchiolitis following BuCy compared to Cy/TBI, 22 the high incidences detected in that report have not been previously appreciated and were not seen in the present study.
Isolated reports of non-engraftment with sibling donors 17 and other specific complications raise the issue of uniform and appropriate dosing of Bu and Cy. Dosing is variable at different centers and IBW, RBW, AIBW, or other parameters of body size may be utilized. Such differences might account for variations in results, not only in CML but in other diseases as well. Based on pharmacokinetic data, 38 we recommend the use of AIBW in all patients. At the least, all reports using BuCy should include the specific body size parameter utilized for dose calculations. The present study emphasizes the influence of other factors which vary between centers, eg GVHD prevention regimen, on LFS and on complications, including chronic GVHD. The use of corticosteroids shortly after transplantation has been previously recognized to increase the incidence of chronic GVHD. 41, 42 It should be noted that other differences in practice over time beside the alteration of the GVHD prevention regimen could have influenced the incidence of chronic GVHD in the present study.
The favorable results attained in the present study were achieved without busulfan plasma level-based dose adjustment. This technique may further improve effectiveness and minimize toxicity. [43] [44] [45] Intravenous busulfan is associated with less variability in plasma levels 46 and a lower incidence of hepatic VOD, 47 perhaps in part by eliminating the first pass effect of orally administered busulfan. It also offers the opportunity for meaningful study of optimal bus-Bone Marrow Transplantation ulfan dose and schedule. Thus, further refinement of the BuCy 2 regimen promises to improve the favorable results reported here.
